TY - JOUR
T1 - Effect of high-dose intravenous iron injection on hepatic function in a rat model of cirrhosis
AU - Kwon, Ji Hye
AU - Kang, Ryung A.
AU - Lee, Sangmin Maria
AU - Hahm, Tae Soo
AU - Cho, Hyun Sung
AU - Jin, Gayoung
AU - Ko, Justin Sangwook
N1 - Publisher Copyright:
© The Author(s) 2024.
PY - 2024/5
Y1 - 2024/5
N2 - Objective: To investigate the hepatic effects of high-dose intravenous (IV) iron, including those on liver function and the degree of fibrosis, in a rat model of cirrhosis. Methods: We evenly allocated 25 Sprague–Dawley rats into five groups: normal rats (control group), cirrhotic rats receiving IV normal saline (liver cirrhosis [LC] group), and cirrhotic rats receiving 20, 40, or 80 mg/kg IV ferric carboxymaltose (LC-iron20, LC-iron40, and LC-iron80 group, respectively). Biochemical parameters were compared at 0, 7, 14, 21, and 28 days. The degrees of hepatic fibrosis and iron deposition were evaluated. Inflammatory and oxidative stress markers were also compared. Results: There were no significant differences in the 28-day serum alanine aminotransferase levels among the LC-iron20, LC-iron40, and LC-iron80 groups (69 ± 7, 1003 ± 127, 1064 ± 309, 919 ± 346, and 820 ± 195 IU/L in the control, LC, LC-iron20, LC-iron40, and LC-iron80 groups, respectively). Hepatic iron accumulation increased in a dose-dependent manner, but the degree of hepatic fibrosis was comparable among the groups. The inflammatory and oxidative stress marker levels did not differ significantly according to the IV iron dose. Conclusions: Administration of IV iron at various high doses appears safe in our rat model of cirrhosis.
AB - Objective: To investigate the hepatic effects of high-dose intravenous (IV) iron, including those on liver function and the degree of fibrosis, in a rat model of cirrhosis. Methods: We evenly allocated 25 Sprague–Dawley rats into five groups: normal rats (control group), cirrhotic rats receiving IV normal saline (liver cirrhosis [LC] group), and cirrhotic rats receiving 20, 40, or 80 mg/kg IV ferric carboxymaltose (LC-iron20, LC-iron40, and LC-iron80 group, respectively). Biochemical parameters were compared at 0, 7, 14, 21, and 28 days. The degrees of hepatic fibrosis and iron deposition were evaluated. Inflammatory and oxidative stress markers were also compared. Results: There were no significant differences in the 28-day serum alanine aminotransferase levels among the LC-iron20, LC-iron40, and LC-iron80 groups (69 ± 7, 1003 ± 127, 1064 ± 309, 919 ± 346, and 820 ± 195 IU/L in the control, LC, LC-iron20, LC-iron40, and LC-iron80 groups, respectively). Hepatic iron accumulation increased in a dose-dependent manner, but the degree of hepatic fibrosis was comparable among the groups. The inflammatory and oxidative stress marker levels did not differ significantly according to the IV iron dose. Conclusions: Administration of IV iron at various high doses appears safe in our rat model of cirrhosis.
KW - end-stage liver disease
KW - Intravenous iron therapy
KW - iron deficiency anemia
KW - liver function
KW - rat model of cirrhosis
KW - transfusion-free surgery
UR - https://www.scopus.com/pages/publications/85194873143
U2 - 10.1177/03000605241253733
DO - 10.1177/03000605241253733
M3 - Article
C2 - 38811356
AN - SCOPUS:85194873143
SN - 0300-0605
VL - 52
JO - Journal of International Medical Research
JF - Journal of International Medical Research
IS - 5
ER -